Explanipedia

Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial Open

Barry A. Borlaug, Jeffrey M. Testani, Mark C. Petrie, Zhenzhong Wang, Jonathan W. Cunningham , et al. · 2025

Relaxin is a peptide hormone that may decrease circulatory congestion and improve kidney function. In this study, we conducted a double-blind, international, multicenter trial to test whether volenrelaxin, a long-acting form of human relax…

Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study Open

Mohit Pahuja, Eric Leifer, John‐Ross D. Clarke, Tariq Ahmad, Melissa A. Daubert , et al. · 2025

Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction Open

Andrew Sherwood, James A. Blumenthal, Robert J. Mentz, Gary G. Koch, Joseph G. Rogers , et al. · 2024

Aims The objective of this study was to examine associations between elevated depressive symptoms and increased risk of adverse clinical events patients with heart failure and reduced ejection fraction (HFrEF), as well as the potential con…

Effective medications can work only in patients who take them: Implications for post‐acute heart failure care Open

Gad Cotter, Beth A. Davison, Kirkwood F. Adams, Andrew P. Ambrosy, L. S. Atabaeva , et al. · 2023

Acute heart failure (AHF) remains a predominant cause of hospitalization, especially among individuals aged 65 years or older, contributing to millions of hospitalizations per year globally.1, 2 Despite advances in therapeutic approach, AH…

Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF Open

Andrew Sherwood, James A. Blumenthal, Robert J. Mentz, Gary G. Koch, Joseph G. Rogers , et al. · 2023

BACKGROUND Prior studies have demonstrated an association of depression with adverse clinical outcomes in patients with HFrEF, but the possible mechanisms responsible for the association are not unserstood. METHODS 142 men and women with H…

The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF Open

Kieran F. Docherty, John J.V. McMurray, Rafael Díaz, G. Michael Felker, Marco Metra , et al. · 2023

Hospitalized patients with HF with reduced ejection fraction had a higher rate of the primary outcome than outpatients. Omecamtiv mecarbil decreased the risk of the primary outcome both when initiated in hospitalized patients and in outpat…

Common Variants on <i>FGD5</i> Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial Open

Hongsheng Gui, W.H. Wilson Tang, Stephan Francke, Jia Li, Ruicong She , et al. · 2023

BACKGROUND: Heart failure remains a global health burden, and patients hospitalized are particularly at risk, but genetic associates for subsequent death or rehospitalization are still lacking. METHODS: The genetic substudy of the ASCEND-H…

Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction Open

David E. Lanfear, Joyce Njoroge, Kirkwood F. Adams, Inder S. Anand, James C. Fang , et al. · 2023

GALACTIC-HF enrolled more Black patients than other recent HF trials. Black patients treated with omecamtiv mecarbil had similar benefit and safety compared with White counterparts.

Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure Open

Robert J. Mentz, Kevin J. Anstrom, Eric L. Eisenstein, Shelly Sapp, Stephen J. Greene , et al. · 2023

Importance Although furosemide is the most commonly used loop diuretic in patients with heart failure, some studies suggest a potential benefit for torsemide. Objective To determine whether torsemide results in decreased mortality compared…

Use of <span>patient‐reported</span> outcomes in heart failure: from clinical trials to routine practice Open

Gianluigi Savarese, JoAnn Lindenfeld, Davide Stolfo, Kirkwood F. Adams, Tariq Ahmad , et al. · 2023

Heart failure (HF) is a complex syndrome that affects mortality/morbidity and acts at different levels in the patient's life, resulting in a drastic impairment in multiple aspects of daily activities (e.g. physical, mental/emotional, and s…

Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure Open

Josephine Harrington, Andrew B. Nixon, Melissa A. Daubert, Eric Yow, James L. Januzzi , et al. · 2023

Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: insights from the GALACTIC‐HF trial Open

Kieran F. Docherty, John J.V. McMurray, Brian Claggett, Zi Michael Miao, Kirkwood F. Adams , et al. · 2023

Aim N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is predictive of both outcomes and response to treatment in patients with heart failure with reduced ejection fraction (HFrEF). The aim of this study was to examine the effect of th…

Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies) Open

Beth A. Davison, Koji Takagi, Christopher Edwards, Kirkwood F. Adams, Javed Butler , et al. · 2022

The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial Open

Justin A. Ezekowitz, Wendimagegn Alemayehu, Sarah Rathwell, Andrew Grant, Mona Fiuzat , et al. · 2021

Aims N‐terminal pro‐b‐type natriuretic peptide (NT‐proBNP) values may be influenced by patient factors beyond the severity of illness, including atrial fibrillation (AF), renal dysfunction, or increased body mass index (BMI). We hypothesiz…

Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure Open

Anne Taylor, Susan Ziesche, Clyde W. Yancy, Peter E. Carson, Ralph D apos Agostino , et al. · 2021

BACKGROUND We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS A…

Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure Patients Open

Javed Butler, James B. Young, William T. Abraham, Robert C. Bourge, Kirkwood F. Adams , et al. · 2021

OBJECTIVES The purpose of this study was to determine the effect of beta-blocker therapy on outcomes of hospitalized heart failure (HF) patients enrolled in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterizat…

Outcomes by Gender in the African-American Heart Failure Trial Open

Anne Taylor, JoAnn Lindenfeld, Susan Ziesche, Mary Norine Walsh, Judith E. Mitchell , et al. · 2021

OBJECTIVES Previous trials testing isosorbide dinitrate/hydralazine (I/H) were performed in all-male study cohorts, and thus the efficacy of I/H in women was unknown; 40% of the A-HeFT (African-American Heart Failure Trial) cohort were wom…

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: Correlation with outcomes Open

Marco Metra, Gad Cotter, Beth A. Davison, G. Michael Felker, Gerasimos Filippatos , et al. · 2021

OBJECTIVES: The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to 180-day mortality in patients with acute heart failure. BACKGROUND: Hospitalization…

Influence of Blood Pressure on the Effectiveness of a Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial Open

Inder S. Anand, S. William Tam, Thomas S. Rector, Anne Taylor, Michael L. Sabolinski , et al. · 2021

OBJECTIVES: This study sought to assess the effect of baseline systolic blood pressure (SBP) and changes in SBP on the effectiveness of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patients wit…

Hormone replacement therapy is associated with improved survival in women with advanced heart failure Open

JoAnn Lindenfeld, Jalal K. Ghali, Heidi Krause‐Steinrauf, Steven S. Khan, Kirkwood F. Adams , et al. · 2021

OBJECTIVES: We sought to determine whether hormone replacement therapy (HRT) is associated with an improved prognosis in women with advanced heart failure (HF) and systolic dysfunction. BACKGROUND: There are about two million postmenopausa…

Patients With Mild Heart Failure Worsen During Withdrawal From Digoxin Therapy Open

Kirkwood F. Adams, Mihai Gheorghiade, Barry F. Uretsky, James B. Young, Sagir Ahmed , et al. · 2021

OBJECTIVES: We investigated whether patients with mild heart failure due to left ventricular systolic dysfunction were at risk of worsening during digoxin withdrawal. BACKGROUND: Deterioration during digoxin withdrawal is often believed to…

Gender differences in advanced heart failure: insights from the BEST study Open

Jalal K. Ghali, Heidi Krause‐Steinrauf, Kirkwood F. Adams, Steven S. Khan, Yves Rosenberg , et al. · 2021

OBJECTIVES: The goal of this study was to determine the influence of gender on baseline characteristics, response to treatment, and prognosis in patients with heart failure (HF) and impaired left ventricular ejection fraction (LVEF). BACKG…

Influence of calcium administration on the short-term hemodynamic and anti-ischemic effects of nifedipine Open

David Wohns, J. Herbert Patterson, Susan Clarke, Stephanie H. Dunlap, Mary Beth Blauwet , et al. · 2021

This prospective study investigated whether pretreatment with intravenously administered calcium would influence the effect of nifedipine on rest hemodynamics and treadmill performance in patients with ischemic heart disease. Seventeen pat…

Clinical benefits of low serum digoxin concentrations in heart failure Open

Kirkwood F. Adams, Mihai Gheorghiade, Barry F. Uretsky, J.Herbert Patterson, Todd A. Schwartz , et al. · 2021

OBJECTIVES: We sought to determine whether there was a relationship between serum digoxin concentration (SDC), including SDCs typically regarded as low, and clinical efficacy related to digoxin in patients with symptomatic left ventricular…

Anemia as a risk factor and therapeutic target in heart failure Open

G. Michael Felker, Kirkwood F. Adams, Wendy A. Gattis, Christopher O apos Connor · 2021

Anemia has recently been recognized as an important comorbid condition and potentially novel therapeutic target in patients with heart failure (HF). Anemia is common in HF patients, with a prevalence ranging from 4% to 55% depending on the…

Association of body mass, gender and race with heart failure primarily due to hypertension Open

Stephanie H. Dunlap, Carla A. Sueta, Lisa Tomasko, Kirkwood F. Adams · 2021

OBJECTIVES: This study was performed to determine the association between clinical characteristics, particularly body mass and race, and the likelihood of hypertension as the primary etiology for heart failure (HTNCM). BACKGROUND: Although…

Effect of Nesiritide in Patients with Acute Decompensated Heart Failure Open

C. M. O'Connor, Robert Starling, Antonio F. Rodríguez Hernández, Patricia Armstrong, Kenneth Dickstein , et al. · 2021

BACKGROUND Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent. ME…

Relation Between Gender, Etiology and Survival in Patients With Symptomatic Heart Failure Open

Kirkwood F. Adams, Stephanie H. Dunlap, Carla A. Sueta, S. W. Clarke, J. Herbert Patterson , et al. · 2021

OBJECTIVES: This study investigated the relation between gender, etiology and survival in patients with symptomatic heart failure. BACKGROUND: Previous work provides conflicting results concerning the relation between gender, clinical char…

Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction Open

Melissa A. Daubert, Eric Yow, Huiman X. Barnhart, Ileana L. Piña, Tariq Ahmad , et al. · 2021

Background NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) is a prognostic biomarker in heart failure (HF) with reduced ejection fraction. However, it is unclear whether there is a sex difference in NT‐proBNP response and whether the…

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Open

John R. Teerlink, Rafael Díaz, G. Michael Felker, John J.V. McMurray, Marco Metra , et al. · 2020

Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by A…

Kirkwood F. Adams YOU? Author Swipe